ZLDPF Zealand Pharma A/S

Zealand Pharma convenes its Annual General Meeting 2025

Zealand Pharma convenes its Annual General Meeting 2025

Company Announcement – No. 3 / 2025

Zealand Pharma convenes its Annual General Meeting 2025

Notice to convene the Annual General Meeting 2025 of Zealand Pharma A/S (CVR no. 20 04 50 78) (the "Company").

The Board of Directors of the Company hereby convenes the Annual General Meeting of the Company to be held on:

Thursday, March 27, 2025 at 3:00 pm (CET)

The Annual General Meeting will be held as a partly electronic general meeting with the possibility of attending electronically or in person (hybrid meeting).

The Annual General Meeting will be held electronically via the virtual portal hosted by Computershare A/S, and physically at the Company's registered address Sydmarken 11, DK-2860 Søborg.

Please find further information in the accompanying attachment.

Attachment



EN
20/02/2025

Underlying

ZLDPFZealand Pharma A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zealand Pharma A/S

 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Total number of shares and voting rights in Zealand Pharma as of March...

Total number of shares and voting rights in Zealand Pharma as of March 31, 2025 Company announcement – No. 8 / 2025 Total number of shares and voting rights in Zealand Pharma as of March 31, 2025 Copenhagen, Denmark, March 31, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar ...

March 31, 2025 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Resolutions from Zealand Pharma's Annual General Meeting 2025

Resolutions from Zealand Pharma's Annual General Meeting 2025 Company announcement – No. 7 / 2025 Resolutions from Zealand Pharma's Annual General Meeting 2025 Copenhagen, Denmark, March 27, 2025 - Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today held its Annual General Meeting of 2025 as a partly electronic and partly physical general meeting (hybrid meeting). At the Annual General Meeting, all proposals presented to the Annual General Meeting were approved. P...

March 27, 2025 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma major shareholder announcement: Van Herk Investments B....

Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Company announcement – No. 6 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, March 25, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 24 March 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 24 March 2025, Van Herk Investments B.V. (Dutch ...

March 25, 2025 1 EN
Guy Sips ... (+5)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Thomas Couvreur
  • Wim Hoste
AGFB AGFA-GEVAERT NV
GREEN GREENYARD NV
ZLDPF ZEALAND PHARMA A/S
DSFIR KONINKLIJKE DSM N.V.
03/25/25 March 25, 2025 1 EN
Jacob Mekhael
  • Jacob Mekhael
ZLDPF Zealand Pharma ...

Zealand Pharma Model update reflects added value of Roche deal

Following Zealand's recent partnership announcement to co-develop and co-commercialise petrelintide with Roche, we dive deeper into the details of the deal and provide an up to date view on the status of Zealand's key programs in obesity. Additionally, we update our model to incorporate the cash injection and milestones, while also increasing our R&D, SG&A and peak sales estimates for petrelintide. All in all, we land at a higher TP of DKK 1120 (from DKK 970), and reiterate our Buy rating. For t...

ZLDPF ZEALAND PHARMA A/S
03/25/25 March 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch